Three Peptides from Soy Glycinin Modulate Glucose Metabolism in Human Hepatic HepG2 Cells by C. Lammi et al.
Article
Three Peptides from Soy Glycinin Modulate Glucose
Metabolism in Human Hepatic HepG2 Cells
Carmen Lammi, Chiara Zanoni and Anna Arnoldi *
Received: 10 August 2015 ; Accepted: 5 November 2015 ; Published: 16 November 2015
Academic Editors: Gopinadhan Paliyath and Antonio Segura-Carretero
Department of Pharmaceutical Sciences, University of Milan, Mangiagalli Street 25, 20133 Milan, Italy;
carmen.lammi@unimi.it (C.L.); chiara.zanoni1@unimi.it (C.Z.)
* Correspondence: anna.arnoldi@unimi.it; Tel.: +39-02-5031-9372; Fax: +39-02-5031-9343
Abstract: Ile-Ala-Val-Pro-Gly-Glu-Val-Ala (IAVPGEVA), Ile-Ala-Val-Pro-Thr-Gly-Val-Ala
(IAVPTGVA) and Leu-Pro-Tyr-Pro (LPYP), three peptides deriving from soy glycinin hydrolysis,
are known to regulate cholesterol metabolism in human hepatic HepG2 cells. We have
recently demonstrated that the mechanism of action involves the activation of adenosine
monophosphate-activated protein kinase (AMPK). This fact suggested a potential activity of
the same peptides on glucose metabolism that prompted us to also investigate this aspect in the
same cells. After treatment with IAVPGEVA, IAVPTGVA and LPYP, HepG2 cells were analyzed
using a combination of molecular techniques, including western blot analysis, glucose uptake
experiments and fluorescence microscopy evaluation. The results showed that these peptides are
indeed able to enhance the capacity of HepG2 cells to uptake glucose, via glucose transporter 1
GLUT1 and glucose transporter 4 GLUT4 activation, through the stimulation of protein kinase B
Akt and adenosine monophosphate-activated protein kinase AMPK pathways, both involved in
glucose metabolism.
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1. Introduction
Soy foods provide useful health benefits [1–3], especially in the area of hypercholesterolemia
prevention [4,5]. In the framework of a research aimed at assessing the role of proteins and
peptides in this activity [6–8], we have recently characterized the molecular mechanism through
which three peptides deriving from soy glycinin digestion with trypsin or pepsin, namely:
Ile-Ala-Val-Pro-Gly-Glu-Val-Ala (IAVPGEVA), Ile-Ala-Val-Pro-Thr-Gly-Val-Ala (IAVPTGVA) and
Leu-Pro-Tyr-Pro (LPYP) [9], modulate cholesterol metabolism in HepG2 cells [10]. These peptides
were selected because preceding investigations by other Authors had shown that they inhibit in vitro
the activity of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCoAR) [9,11,12]. Our experiments
have demonstrated that these peptides are able to increase the low density lipoprotein (LDL)
receptor (LDLR) protein level, with the consequence of an enhanced capacity of HepG2 cells to
uptake LDL [10]. In the same paper, we have also shown that the regulation of cholesterol
metabolism involves the activation of adenosine monophosphate-activated protein kinase (AMPK),
an observation that suggested that IAVPGEVA, IAVPTGVA and LPYP may also modulate glucose
metabolism [10]. In fact, there is substantial evidence that AMPK is dysregulated in animal models
and humans affected by the metabolic syndrome or type-2 diabetes and that the physiological or
pharmacological activation of AMPK may improve insulin sensitivity and metabolic health [13].
AMPK activation leads to the inhibition of hepatic glucose production and stimulation of glucose
uptake in hepatic cells, which helps to maintain the correct glycemia [14]. AMPK is therefore
becoming an attractive target for type-2 diabetes therapies.
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Regulation of glucose uptake from the blood and metabolism in peripheral tissues are key
steps in maintaining a healthy metabolic phenotype. Glucose uptake into cells is facilitated and
tightly controlled by glucose transporters that show diverse expressions among different tissues [15].
In general, a specific isoform, such as GLUT4, is activated in response to insulin through the
activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-protein kinase B (Akt) pathway.
In response to insulin, the Akt activation, through phosphorylation at serine 473, leads to a
translocation of GLUT4 on cellular membranes. Moreover, active Akt leads to an increase of glycogen
synthase (GS) activity by phosphorylation/inhibition of glycogen synthase kinase 3 (GSK3). Active
GS is then able to carry out the glycogen production from glucose.
HepG2 cells, which are a suitable cell model for studying certain function of human hepatocytes,
show a blunted response to insulin and, in general, the glucose uptake is facilitated by GLUT1,
which is highly expressed in the human hepatocytes and HepG2 cells as well [16]. Interestingly,
the stimulation of AMPK activity is associated with enhancement of GLUT1-mediated glucose
transport [17]. All these factors make the well-understood HepG2 model suitable for carrying out
experiments to assess glucose uptake and metabolism [17].
Moreover, increasing evidences suggest that increased AMPK activity is associated with
increased GLUT4 gene expression without involvement of insulin [18]. Furthermore, treatment
with the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) results in
increased GLUT4 gene expression in specific tissues, such as skeletal muscle [19], even though the
underlying molecular mechanisms mediating this response are still unknown.
Interestingly, a few published studies provided evidence that soy peptides and/or proteins may
exert a hypoglycemic activity either in animals [20,21] or in type-2 diabetic patients [22,23] and
peptide mixtures obtained by pepsin-pancreatic hydrolysis of soy protein improve glucose uptake
in muscle L6 cells [24].
Taking into account all these evidences, the objectives of the present investigation were twofold:
(a) to verify whether IAVPGEVA, IAVPTGVA and LPYP are able to modulate glucose metabolism in
HepG2 cells; (b) to accomplish a molecular characterization of the stimulated pathways.
2. Results and Discussion
In order to examine whether IAVPGEVA, IAVPTGVA and LPYP may affect the activation of
Akt and GSK3αβ (its direct substrate and major target), western blot analyses were performed on
lysates from treated HepG2 cells using antibodies specific for Akt phosphorylated at serine 473 and
for GSK3αβ phosphorylated at serines 21 and 9, respectively. The results (Figure 1) suggest that
these peptides activate the Akt pathway, since the treatments with IAVPGEVA, IAVPTGVA and
LPYP significantly increased the level of phosphorylated Akt by 76%, 96% and 77%, respectively,
versus the untreated sample. Akt activation determined in turn the inhibition of GSK3αβ activity
by phosphorylation at (Ser 21/9) by 57%, 53% and 76%, respectively, versus the untreated sample
(Figure 1). The final consequence of GSK3 inactivation by Akt is the promotion of glucose storage
as glycogen, because GS, an enzyme that catalyzes the final step in glycogen synthesis, is a major
substrate of GSK3 [25].
As already explained in the introduction, in a previous paper [10] we demonstrated that
IAVPGEVA, IAVPTGVA and LPYP activate AMPK through phosphorylation of threonine 172 by 79%,
51% and 100%, respectively, versus untreated samples in HepG2 cells. The Akt and AMPK pathway
activation suggested investigating the effects of these peptides on the GLUT4 and GLUT1 protein
levels, using immunoblot experiments based on specific primary antibodies. Figure 2A–C indicates
that IAVPGEVA increased the GLUT4 protein level by 19%, IAVPTGVA by 34% and LPYP by 135%;
whereas Figure 2B–D shows that they significantly increased the GLUT1 protein level by 80%, 106%
and 52%, respectively, versus the untreated sample.
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Figure 1. Effect of peptides on Akt/glycogen synthase kinase 3 αβ (Akt/GSK3αβ) pathway. HepG2 
cells (1.5 × 105) were treated with Ile-Ala-Val-Pro-Gly-Glu-Val-Ala (IAVPGEVA) (500 μM), Ile-Ala-
Val-Pro-Thr-Gly-Val-Ala (IAVPTGVA) (500 μM) and Leu-Pro-Tyr-Pro (LPYP) (500 μM) for 24 h. (A,B) 
Exemplary western blot analyses of phosphorylated Akt (Ser473) and phosphorylated GSK3αβ 
(Ser21/9) levels after treatment. Signals were detected using specific anti-phospho-Akt (Ser473), anti-
phospho-GSK3αβ (Ser21/9) and anti-β-actin primary antibodies (loading untreated sample); (C,D) 
Quantitative analyses of western blots. Phospho-Akt (Ser473) and phospho-GSK3αβ (Ser21/9) band 
intensities were quantified by ChemiDoc (BioRad, Hercules, CA, USA) and normalized using β-actin 
signals. Bars represent averages of duplicate samples ± SEM of six independent experiments. * p < 
0.05, ** p < 0.001 *** p < 0.0001 versus untreated sample. C, untreated sample; pAkt, phosphor-Akt; 
pGSK3αβ, phospho-GSK3αβ. 
 
Figure 2. Effect of peptides on glucose transporter 4 (GLUT4) and glucose transporter 1 (GLUT1) 
protein levels. HepG2 cells (1.5 × 105) were treated with IAVPGEVA (500 μM), IAVPTGVA (500 μM) 
and LPYP (500 μM) for 24 h. (A,B) Exemplary western blot analyses of GLUT4 and GLUT1 after 
treatment. Signals were detected using specific anti-GLUT4, anti-GLUT1 and anti-β-actin primary 
antibodies (loading untreated sample); (C,D) Quantitative analyses of immunoblots. GLUT4 and 
GLUT1 band intensities were quantified by ChemiDoc (BioRad, Hercules, CA, USA) and normalized 
using β-actin signals. Bars represent averages of duplicate samples ± SEM of seven independent 
experiments. * p < 0.05, ** p < 0.001 versus untreated sample. C, untreated sample. 
Figure 1. Effect of peptides on Akt/glycogen synthase kinase 3 αβ (Akt/GSK3αβ) pathway.
HepG2 cells (1.5 ˆ 105) were treated with Ile-Ala-Val-Pro-Gly-Glu-Val-Ala (IAVPGEVA) (500 µM),
Ile-Ala-Val-Pro-Thr-Gly-Val-Ala (IAVPTGVA) (500 µM) and Leu-Pro-Tyr-Pro (LPYP) (500 µM) for
24 h. (A,B) Exemplary western blot analyses of phosphorylated Akt (Ser473) and phosphorylated
GSK3αβ (Ser21/9) levels after treatment. Signals were detected using specific anti-phospho-Akt
(Ser473), anti-phospho-GSK3αβ (Ser21/9) and anti-β-actin primary antibodies (loading untreated
sample); (C,D) Quantitative analyses of western blots. Phospho-Akt (Ser473) and phospho-GSK3αβ
(Ser21/9) band intensities were quantified by ChemiDoc (BioRad, Hercules, CA, USA) and
normalized using β-actin signals. Bars represent averages of duplicate samples ˘ SEM of six
independent experiments. * p < 0.05, ** p < 0.001 *** p < 0.0001 versus untreated sample. C, untreated
sample; pAkt, phosphor-Akt; pGSK3αβ, phospho-GSK3αβ.
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Figure 2. Effect of peptides on glucose transporter 4 (GLUT4) and glucose transporter 1 (GLUT1)
protein levels. HepG2 cells (1.5 ˆ 105) were treated with IAVPGEVA (500 µM), IAVPTGVA (500 µM)
and LPYP (500 µM) for 24 h. (A,B) Exemplary western blot analyses of GLUT4 and GLUT1 after
treatment. Signals were detected using specific anti-GLUT4, anti-GLUT1 and anti-β-actin primary
antibodies (loading untreated sample); (C,D) Quantitative analyses of immunoblots. GLUT4 and
GLUT1 band intensities were quantified by ChemiDoc (BioRad, Hercules, CA, USA) and normalized
using β-actin signals. Bars represent averages of duplicate samples ˘ SEM of seven independent
experiments. * p < 0.05, ** p < 0.001 versus untreated sample. C, untreated sample.
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These findings clearly suggest that each soy peptide increases either the GLUT4 or GLUT1
protein levels, but with some differences, since the level of GLUT1, the main isoform responsible
for glucose entry into HepG2 cells [16], is enhanced more by IAVPGEVA and IAVPTGVA, whereas
the level of GLUT4 is increased much more efficiently by LPYP. Based on these molecular
results, qualitative and quantitative experiments were carried out in order to evaluate whether the
treatments with these peptides change the functional capability of HepG2 cells to uptake extracellular
fluorescent glucose, i.e., 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG).
After incubation of HepG2 cells with each peptide for 24 h, the qualitative analysis of glucose uptake
by microscopy (Figure 3A) showed that indeed IAVPGEVA, IAVPTGVA and LPYP increase the
glucose uptake versus untreated sample in HepG2 cells, whereas quantitative data obtained detecting
fluorescence signals by a plate reader (Figure 3B) indicated that the 2-NBDG uptake increase is
statistically significant. The treatments with 50 µM IAVPGEVA and IAVPTGVA led to a glucose
uptake increase by 180% and 298%, respectively, versus the untreated sample, whereas after treatment
with 100 µM LPYP the glucose uptake was increased by 158% versus the untreated sample.
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Figure 3. Qualitative and quantitative fluorescent glucose uptake analysis. (A) Qualitative uptake. 
The first column (a,d,g,j) represents fluorescence signals of DAPI staining for each peptide. The 
second column (b,e,h,k) represents fluorescent glucose, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose (2-NBDG) signals for each peptide (exciting at 485 nm). The third column 
(c,f,i,l) is the merge of the first and second column (blue signal is DAPI; green signal is glucose 
staining). Fluorescence images of 20× magnification areas were collected using a Zeiss Axioplan 2 
microscope; (B) Quantitative analysis of glucose uptake. HepG2 cells (3 × 104) were cultured in 
complete growth medium, then after 2d treated with IAVPGEVA (50 μM), IAVPTGVA (50 μM) and 
LPYP (100 μM) for 24 h. The day after, the medium was removed and fluorescent glucose (2-NBDG) 
(100 μg/mL) was added. After 10 min, excess of 2-NBDG was removed and cells were washed twice 
with cell based assay buffer. Fluorescent glucose uptake signal was measured by Synergy H1 (Biotek, 
Winooski, VT, USA). Data points represent averages ± SEM of three independent experiments in 
triplicate. * p < 0.05, *** p < 0.0001 versus untreated sample. C, untreated sample. 
These soy peptides appear to modulate the glucose metabolism and uptake through the 
activation of Akt and AMPK pathway. In more detail, the activation of Akt, through an increase of 
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uptake. The first column (a,d,g,j) represents fluorescence signals of DAPI staining for each peptide.
The second column (b,e,h,k) represents fluorescent glucose, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-2-deoxyglucose (2-NBDG) signals for each peptide (exciting at 485 nm). The third column
(c,f,i,l) is the merge of the first and second column (blue signal is DAPI; green signal is glucose
staining). Fluorescence images of 20ˆ magnification areas were collected using a Zeiss Axioplan 2
microscope; (B) Quantitative analysis of glucose uptake. HepG2 cells (3 ˆ 104) were cultured in
complete growth medium, then after 2d treated with IAVPGEVA (50 µM), IAVPTGVA (50 µM) and
LPYP (100 µM) for 24 h. The day after, the medium was removed and fluorescent glucose (2-NBDG)
(100 µg/mL) was added. After 10 min, excess of 2-NBDG was removed and cells were washed twice
with cell based assay buffer. Fluorescent glucose uptake signal was measured by Synergy H1 (Biotek,
Winooski, VT, USA). Data points represent averages ˘ SEM of three independent experiments in
triplicate. * p < 0.05, *** p < 0.0001 versus untreated sample. C, untreated sample.
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These soy peptides appear to modulate the glucose metabolism and uptake through the
activation of Akt and AMPK pathway. In more detail, the activation of Akt, through an increase of
phosphorylation at serine 473, leads to the inhibition of GSK3, which in turn produces a positive
GS regulation and formation of hepatic glycogen. In parallel, the increased GLUT4 and GLUT1
protein levels lead to an improvement of glucose uptake by HepG2 cells, mainly due to the GLUT1
transporter activity on cellular membranes. Based on this evidence, it seems possible to hypothesize
that the ability of these peptides to modulate either glucose or cholesterol metabolism may be due to
the synergic activation of Akt and AMPK.
Figure 4 presents a general picture of the metabolic pathways modulated by these soy peptides
in HepG2 cells. Interestingly, the intracellular pathways involving Akt and AMPK are the same
involved in the hypoglycemic molecular mechanism of some well-known anti-diabetic drugs, such
as metformin [26] and thiazolidinediones [27].
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Figure 4. Potential mechanism of action of soy peptides in HepG2 cells. Upon cell penetration, they 
act as competitive inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCoAR) leading to 
an intracellular cholesterol synthesis reduction. The consequence is the activation of the transcription 
factor sterol regulatory element-binding proteins (SREBP) 2, which leads to low density lipoprotein 
receptor (LDLR) and HMGCoAR genes transcription, with subsequent increase of LDLR and 
HMGCoAR protein levels and LDLR localization in plasma membrane (a); In parallel, soy peptides 
reduce cholesterol production also by activation of the monophosphate-activated protein kinase 
(AMPK) pathway through an increase of phosphorylation at Thr-172, which in turn inactivates its 
target substrate HMGCoAR through phosphorylation at serine-872 and produces an increase of the 
activity of glucose transporters (b); IAVPGEVA, IAVPTGVA and LPYP enhance Akt activation, 
through an increase of phosphorylation at Ser473, which in turn inactivates glycogen synthase kinase 
3 αβ (GSK3αβ), a kinase that contributes to proteasomal degradation of SREBP2 [10,28,29]. Moreover, 
GSK3αβ, inactivated by Akt phosphorylation at Ser21/9, does not inhibit glycogen synthase (its 
substrate) that can convert the increased up-taken glucose in intracellular glycogen (c); Finally, 
extracellular-signal-regulated kinases (ERK) 1/2 pathway activation [10] could lead to stabilization of 
mRNA levels of LDLR contributing to increase LDLR protein levels in plasma membrane (d). Thus, 
the distinct modulation of four pathways leads to an increased LDLR activity, which can bind and 
carry extracellular LDL in HepG2 cells with final hypocholesterolemic effects. Moreover, Akt and 
AMPK pathway activations are correlated with glucose metabolism modulation, which leads to an 
increase of glucose-uptake by human hepatic cells. 
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an intracellular cholesterol synthesis re uction. The consequence is the activation of the transcription
factor sterol regulatory element-binding proteins (SREBP) 2, which leads to low density lipoprotein
receptor (LDLR) and HMGCoAR genes transcription, with subsequent increase of LDLR and
HMGCoAR protein levels and LDLR localization in plasma membrane (a); In parallel, soy peptides
reduce cholesterol production also by activation f the monophosphate-activat d prot in kinase
(AMPK) pathway through an increase of phosphorylation at Thr-172, which in turn inactivates its
target substrate HMGCoAR through phosphorylation at serine-872 and produces an increase of
the activity of glucose transporters (b); IAVPGEVA, IAVPTGVA and LPYP enhance Akt activation,
through an incr ase of phosphorylation at Ser473, which in turn inactivat s glycogen synthase
kinase 3 αβ (GSK3αβ), a kinase that contributes to proteasomal degradation of SREBP2 [10,28,29].
Moreover, GSK3αβ, inactivated by Akt phosphorylation at Ser21/9, does not inhibit glycogen
synthase (its substrate) that can convert the increased up-taken glucose in intracellular glycogen
(c); Finally, extracellular-signal-regulated kinases (ERK) 1/2 pathway activation [10] could lead
to stabilization of mRNA levels of LDLR contributing to increase LDLR protein levels in plasma
membrane (d). Thus, the distinct modulation of four pathways leads to an increased LDLR activity,
which can bind and carry extracellular LDL in HepG2 cells with final hypocholesterolemic effects.
Moreover, Akt and AMPK pathway activations are correlated with glucose metabolism modulation,
which leads to an increase of glucose-uptake by human hepatic cells.
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3. Experimental Section
3.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM), modified Eagle’s medium (MEM),
L-glutamine, fetal bovine serum (FBS), phosphate buffered saline (PBS), penicillin/streptomycin,
chemiluminescent reagent and 96-well plates were purchased from Euroclone (Milan, Italy). Bovine
serum albumin (BSA), RIPA buffer, the antibody against β-actin were bought from Sigma-Aldrich
(St. Louis, MO, USA). The antibodies rabbit Ig-HRP, mouse Ig-HRP, PMSF, Na-orthovanadate
inhibitors and goat anti-rabbit Ig-HRP were purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). The antibodies against phospho-Akt (Ser473) and GSK3 α/β (Ser21/9)
were purchased from Cell Signaling Technologies (Danvers, MA, USA); whereas the antibodies
against GLUT1 and GLUT4 were purchased from GeneTex (Irvine, CA, USA). The inhibitor cocktail
Complete Midi from Roche (Basel, Switzerland). Mini protean TGX pre-cast gel 7.5% and Mini
nitrocellulose Transfer Packs were purchased from BioRad (Hercules, CA, USA). The 2-NBD-glucose
(2-NBDG) and cell based assay buffer were purchased from Cayman Chemical Company
(Ann Arbor, MI, USA). IAVPGEVA, IAVPTGVA and LPYP were synthesized (>95% purity by
HPLC) by PRIMM (Milan, Italy).
3.2. Cell Culture
The HepG2 cell line was bought from ATCC (HB-8065, ATCC from LGC Standards, Milan,
Italy). It was cultured in high glucose DMEM with stable L-glutamine supplemented with 10% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin (complete growth medium) and incubated at 37 ˝C
under 5% CO2 atmosphere. HepG2 cells were used for no more than 20 passages after thawing,
because the increase of the number of passages may change the cell characteristics and impair
assay results.
3.3. Western Blot Analysis
1.5 ˆ 105 HepG2 cells/well (24-well plate) were treated with IAVPGEVA, IAVPTGVA and LPYP
peptides (each 500 µM, dissolved in water) or with vehicle (water, untreated sample) for 24 h.
At the end of the treatment, cells were scraped in 40 µL ice-cold lysis buffer (RIPA buffer + inhibitor
cocktail + 1:100 PMSF + 1:100 Na-orthovanadate) and transferred in an ice-cold microcentrifuge
tube. After centrifugation at 13,300 rpm for 15 min at 4 ˝C, the supernatant was recovered and
transferred in a new ice-cold tube. Total proteins were quantified by the Bradford method and 50 µg of
total proteins loaded on a pre-cast 7.5% sodium dodecyl sulfate—polyacrylamide (SDS-PAGE) gel at
130 V for 45 min. Subsequently, the gel was pre-equilibrated with 0.04% SDS in H2O for 15 min at
room temperature (RT) and transferred to a nitrocellulose membrane (Mini nitrocellulose Transfer
Packs), using a Trans-blot Turbo at 1.3 A, 25 V for 7 min. Target proteins, on milk blocked membrane,
were detected by primary antibodies as follows: rabbit anti-Akt (Ser473), anti-phospho-GSK3αβ
(Ser21/Ser9), anti-GLUT1, anti-GLUT4 and anti-β-actin. Secondary antibodies conjugated with
HRP and a chemiluminescent reagent were used to visualize target proteins and their signals were
quantified using the Image Lab Software (BioRad, Hercules, CA, USA). The internal control β-actin
was used to normalize loading variations.
3.4. Fluorescent Glucose Uptake Cell Based Assay
3 ˆ 104 HepG2 cells/well were seeded in 96-well plates and kept in complete growth medium
for 2 d before treatment. The third day, cells were washed once with PBS and they were treated
with 50 µM of IAVPGEVA or IAVAPTGVA and 100 µM of LPYP dissolved in water, respectively,
or vehicle (water) in MEM w/o FBS for 24 h. The following day, the medium was removed and
75 µL/well of 2-NBDG (100 µg/mL) in MEM w/o FBS was added for 10 min at 37 ˝C. Excess of
2-NBDG was aspirated without disrupting the HepG2 layer and cells washed twice with 100 µL of
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cell based assay buffer. After that, the degree of glucose uptake was measured and quantified using
the Synergy H1 fluorescent plate reader from Biotek (excitation and emission wavelengths 485 and
535 nm, respectively). Furthermore, the qualitative glucose uptake was evaluated collecting
fluorescent images using Zeiss Axioplan 2 microscope (Oberkochen, Germania). Staining of the
nucleus were carried out incubating for 15 min at RT DAPI solution (30 ng/mL). Images were
captured at 20ˆ magnification areas.
3.5. Statistically Analysis
Statistical analyses were carried out by one-way ANOVA (Graphpad Prism 6 (La Jolla, CA, USA)
followed by Dunnett’s test. Values were expressed as means ˘ SEM; p-values < 0.05 were considered
to be significant.
4. Conclusions
To our knowledge, this is the first report highlighting the activity of some specific peptides from
soy glycinin on glucose metabolism and homeostasis in human hepatic cells. Of course, in order to
evaluate the final relevance of this study, an open issue is the in vivo absorption of these peptides: a
very recent paper has provided some positive hints on the absorption of other soy peptides using
a Caco2 model system [30]. Natural products are a rich source of leading compounds for drug
discovery [31]. In this scenario, these soy peptides might be novel candidates for developing new
compounds able to modulate positively cell-signaling pathways. Indeed, recent literature reports
other examples of natural-product-like compounds acting as modulator of intracellular cell-signaling
pathways [32,33].
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